A plain language summary communicates findings of a scientific study to help people without scientific expertise better understand important progress in the field.

Check out our top plain language summaries + learn from these studies at #ASGCT2024 . bit.ly/3QnjHlx

Today U.S. FDA approved #Beqvez , a #genetherapy for #hemophiliaB . The therapy is designed to stimulate production of the factor IX protein by the patient's own body. Pfizer Inc. says it will be available by prescription to eligible patients this quarter. reut.rs/4aX1u6r

.Children's Hospital researchers demonstrated improved quality of life for #sicklecelldisease patients with recurrent vaso-occlusive crises. The findings provide the complete details of the trial leading to U.S. FDA approval of #Casgevy in Dec. 2023. bit.ly/3Uw3SLA

“When you want something and work hard to make it happen, I promise you will always find someone who’s going to give you the opportunity and support your needs.”

Catch Ruth Castellanos, PhD, at this year's #ASGCT2024 Women's Reception on May 9! bit.ly/3xSQM2c

There are still spots left at the #ASGCT2024 Closing Night Reception on Friday, May 10! Join us to celebrate the end of the meeting with food and music at Power Plant Live! in downtown Baltimore.

Add on a ticket to your meeting registration! bit.ly/3UyttDK

Listen to a preview of the most intriguing + promising abstracts at #ASGCT2024 with ASGCT Members Lynnea Olivarez, Emily Walsh, + host Christopher Leidli! Hear about what they're looking forward to most, tips, and much more. bit.ly/4dcWFHU

The #ASGCT2024 abstracts are NOW available! Use our interactive search tool or download a PDF to view more than 1,800 new pieces of #genetherapy + #celltherapy research. bit.ly/3U2GDaE

VCAM-targeting lipid platform brings new hope to the treatment of ischemic stroke dlvr.it/T5dwPx #genetherapy #celltherapy

The CGT Science Series with U.S. FDA is back for a third seminar! This round focused on the recent #CMC guidance for cell and #genetherapies , featuring Dr. Andrew Byrnes; watch it now! bit.ly/4aYHD6C #ASGCTadvocacy

Check out the full #ASGCT2024 program available now! Search 200+ hours of sessions by keyword in the interactive agenda online or print out the PDF version to plan your time at the meeting!

Make sure you're registered + we'll see you in Baltimore! bit.ly/3HFSrdi

The April issue of The Advocate is out now! In this issue: Watch our Congressional briefing on #geneediting , read our comments to U.S. FDA on potency assurance for #CGT products, and more! Subscribe + view on our website. #ASGCTadvocacy bit.ly/49Fmkpl

'Could we get to a point someday where we can use genome editing as a prophylactic to protect ourselves from disease?'

-Nobel Laureate and #CRISPR pioneer Jennifer Doudna Innovative Genomics Institute in conversation with Eric Topol.
youtube.com/watch?v=D4FOtJ…

Seeking clarity on #potency assurance in cellular and #genetherapy products? ASGCT's comments to U.S. FDA outline specific suggestions for improving the draft guidance. Our members drive progress in the #CGT field. bit.ly/3vWeBFM #ASGCTadvocacy

Our new strategic plan is out now!

Learn how we're driving universal access to #celltherapy and #genetherapy treatments through communication, education, advocacy, and innovation. bit.ly/3JmuCIa

Members + transitional members: VOTE through May 1 to help us decide the future of ASGCT!

We need to fill four spots on our Board of Directors. Check out the slate of candidates here and cast your ballot! bit.ly/3U8pKvo

Tune in to a NEW episode of The Issue for an exceptional discussion on #CMC with Dr. Susan D'Costa (Genezen)!

'Geek out' with Susan and host Emily Walsh, PhD, on the intricacies of defining your CMC strategy. Listen + subscribe. bit.ly/3vTLMK5

#Geneediting has the potential to transform treatment for #rarediseases . A recent Capitol Hill briefing introduced congressional staffers to the underlying science of gene editing + considerations for patients.

Watch now. bit.ly/3Q2utgT #ASGCTadvocacy

Calling all individuals with #rarediseases , their caregivers, + volunteers/employees of nonprofits or disease-specific foundations! TODAY, April 15, is the final day to apply for complimentary registration to #ASGCT2024 .

Learn more + apply! bit.ly/3IwCA13

Our Q1 2024 landscape report with Citeline is available NOW! In the past quarter, the field earned the approval of new therapies in the U.S., Canada, and China.

Read + download the full report. bit.ly/4aSb75X

Congratulations to our 27th Annual Meeting Award Winners! We can't wait to hear from them in just a few weeks at #ASGCT2024 . Learn more about these CGT experts on our blog. bit.ly/49v3ZLS